A number of projects started within the Spring Group have led to ideas with significant commercial applications. Alongside obtaining patents for promising therapeutic research, the Group also encourages members to pursue their ideas outside of academia.
PharmEnable is a drug discovery company using a combination of medicinal chemistry and AI computational approaches to design the next generation of small molecule drugs. Their approach focuses on efficiently mapping the possible chemical space to design complex, 3-dimensional small molecules, inspired by nature. PharmEnable is a spin-out company from the Department of Chemistry in the University of Cambridge, encompassing over two decades of research into diversity-oriented synthesis and world-leading expertise in computational chemistry. During the 2020 UK lockdown, the company secured 1.8 million GBP in seed financing led by Cambridge Enterprise alongside angel investors and life science investment funds.
The Group has recently had members reach the finals of the EPOC Business Plan Competition with new biotech start-up Pep2Smart. Watch this space for news!